Literature DB >> 8608249

Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene.

S Joos1, M I Otaño-Joos, S Ziegler, S Brüderlein, S du Manoir, M Bentz, P Möller, P Lichter.   

Abstract

Primary mediastinal (thymic) B-cell lymphoma is a high-grade non-Hodgkin's lymphoma with unique features. By using comparative genomic hybridization and interphase cytogenetics, 26 tumors were analyzed to identify genomic imbalances. Gains of chromosomal material were much more frequent than losses (110 v 10) and involved chromosomes 9p, 12q, and Xq (31% to 50%). Interestingly, gain of Xq coincided with gain of 9p. Distinct high-level amplifications were found in four subregions. In 2 cases, amplifications of proto-oncogene REL were shown by filter hybridization, indicating a possible pathogenic role of this gene. The characteristic pattern of chromosomal imbalances distinct from other B-cell lymphomas suggests a specific pathway of genetic changes associated with this lymphoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608249

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  High-level DNA amplifications are common genetic aberrations in B-cell neoplasms.

Authors:  C A Werner; H Döhner; S Joos; L H Trümper; M Baudis; T F Barth; G Ott; P Möller; P Lichter; M Bentz
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Chromosomal imbalances in primary lymphomas of the central nervous system.

Authors:  C H Rickert; B Dockhorn-Dworniczak; R Simon; W Paulus
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

3.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Authors:  Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

Review 4.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 5.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

6.  Gene expression, signal transduction pathways and functional networks associated with growth of sporadic vestibular schwannomas.

Authors:  Hjalte C R Sass; Rehannah Borup; Mikkel Alanin; Finn Cilius Nielsen; Per Cayé-Thomasen
Journal:  J Neurooncol       Date:  2016-10-17       Impact factor: 4.130

Review 7.  Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

Review 8.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

Review 9.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

Review 10.  [Grayzone lymphoma. Clinical relevance].

Authors:  S Hartmann; M L Hansmann
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.